Expansion of Dermatology Portfolio Using an Evidence-Based Approach

Certara conducted in-depth interviews with ten US commercial and Medicare payers.

After conducting and analyzing the interviews, Certara;

• Identified efficacy / safety endpoints and additional economic data that would drive value to payers
• Provided a comprehensive assessment of each product concept by payers
• Defined a price range for each product concept and expected formulary access
• Assessed payers’ future priorities in managing and funding treatments for patients in this therapeutic category and identified how this will affect access to the products tested
• Identified products to prioritize based on payer assessment